Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | MicrobiomeTrials← Back to trialsNCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-04-28Est. Completion: 2033-02-23
Enrollment target: 50 participants Locations- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Columbia University Medical Center New York Presbyterian, New York, New York, United States
- Seattle Childrens Hospital, Seattle, Washington, United States
- Novartis Investigative Site, Brisbane, Queensland, Australia
- Novartis Investigative Site, North Adelaide, South Australia, Australia
- Novartis Investigative Site, Edmonton, Alberta, Canada
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Zhengzhou, Henan, China
- Novartis Investigative Site, Tianjin, China
- Novartis Investigative Site, Marseille, France
- Novartis Investigative Site, Paris, France
- Novartis Investigative Site, Poitiers, France
- Novartis Investigative Site, Strasbourg, France
- Novartis Investigative Site, Roma, RM, Italy
- Novartis Investigative Site, Yokohama, Kanagawa, Japan
- Novartis Investigative Site, Fukuoka, Japan
- Novartis Investigative Site, Saitama, Japan
Other microbiome trials you might be interested in
Leukemia, Chronic Myeloid
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic…
Baden-Baden, GermanyEst. completion Sep 30, 2030
Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic Myelodysplasia
Novartis Investigative Site, Utrecht, NetherlandsNovartis Investigative Site, Gdansk, PolandNovartis Investigative Site, Wroclaw, PolandNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Barcelona, SpainNovartis Investigative Site, Madrid, SpainMyeloid Leukemia, Acute
Nonlymphoblastic Leukemia, Acute
Leukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029